Science Looking Forward Subcommittee of the Science Board to the Food and Drug Administration

FDA Science Board Update
03/04/2015
William N. Hait, Jansen R&D (Co-Chair)
Maria C. Freire, Foundation for the NIH
Lynn R. Goldman, George Washington University
Frederick Kushner, Heart Clinic of Louisiana
Mark R. McLellan, Utah State University
Bruce M. Psaty, University of Washington
Alan J. Russell, Carnegie Mellon University
Margaret Anderson, Faster Cures
Peter K. Honig, Pfizer
Barbara J. McNeil, Harvard Medical School
Garry A. Neil, Medgenics
Ellen Sigal, Friends of Cancer Research
Gail Cassell (member of previous “Science and Mission at Risk” subcommittee)

* Roster
AREA I: PRIORITIES, ACTIVITIES, AND EMERGING NEEDS

In August 2011, FDA issued its Strategic Plan for Regulatory Science. FDA will seek the SC’s feedback on how well the Plan captures FDA’s cross-cutting scientific needs, whether modifications should be made to the Plan, and recommendations for what additional steps the Agency could take to best position itself to meet emerging and future trends in science, technology and FDA-regulated products.

Charge
* AREA II: EXTRAMURAL PROGRAMS AND COLLABORATIONS

FDA is currently engaged in extensive collaborations with numerous public and private sector entities. FDA will seek the SC’s input as to opportunities for collaboration, strategies/frameworks for collaboration, and recommendations for potential new collaborations that best advance the Agency’s mission.
AREA III: SUPPORTING AN ENVIRONMENT OF SCIENTIFIC EXCELLENCE

FDA has taken several actions in recent years to foster an environment of scientific excellence. The Agency will seek the SC’s feedback on the actions it has already taken as well as its recommendations for additional steps it could take to further support a culture of scientific excellence and creativity.

Charge
* August, 2014 - Teleconference
* August, 2014 - Virtual Conference (Adobe Connect)
* Questions/Clarifications generated and submitted to FDA November 2014
* Subgroups created for each of the three areas
  * Leads:
    * Area I: Fred Kushner
    * Area II: Maria Freire
    * Area III: Martin Philbert
* Series of Teleconferences in January/February ‘15 with FDA regarding the Progress Report. Additional Information requested.
* Subgroups meeting individually with regular checkpoints with entire subcommittee
* March 31, 2015, Site Visit to FDA
* Compose draft report for submission to Science Board by July 2015

* Future activities